Mural's lead product candidate, nemvaleukin alfa, is in two potentially registrational trials in platinum resistant ovarian cancer and mucosal melanoma, both of which are on track with readouts expected in 1H 2025 A new, less frequent IV dose of nemvaleukin is also being evaluated both as a single agent and in combination with pembrolizumab in patients with cutaneous melanoma with preliminary data readouts anticipated in 2025 In April 2024, Mural presented preclinical data on its investigational engineered ...

FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Registrant's telephone number, including area code: +353-1-905-8020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41837 Mural Oncology plc (Exact name of Registrant as specified in its Charter) Ireland 98-1748617 (State or ...

Financial Position - Mural Oncology reported cash and cash equivalents of $270.9 million as of December 31, 2023[4]. Research and Development - Research and development expenses for Q4 2023 were $42.2 million, primarily due to employee-related expenses and ARTISTRY-7[9]. - Enrollment is ongoing in ARTISTRY-6 and ARTISTRY-7, with ARTISTRY-7 evaluating nemvaleukin in 448 patients with platinum-resistant ovarian cancer[5]. - Mural Oncology plans to present preclinical data for IL-18 and IL-12 at the upcoming AACR conference and nominate development candidates later this year[5]. Operating Expenses - General and administrative expenses for Q4 2023 totaled $16.3 million, including $9.7 million in non-cash, share-based compensation[9]. - The company anticipates lower operating expenses in future quarters following the spin-out from Alkermes[9]. Financial Performance - The net loss for Q4 2023 was $59.5 million, which included $15.2 million in non-cash, share-based compensation[9]. - The company reiterates its cash runway projection into Q4 2025[2]. Future Outlook - The company expects to report top-line data results from cohort 2 of ARTISTRY-6 in the first half of 2025[5]. - Mural Oncology aims to explore partnerships to further investigate the potential of nemvaleukin and its preclinical programs[2].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-41837 Mural Oncology plc (Exact Name of Registrant as Specified in its Charter) (State or ...